Kimberly-Clark
KMB
$109.31
-0.80%
Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm, with iconic brands such as Huggies, Kleenex, and Cottonelle spanning personal care and consumer tissue products. As a dominant player in the household & personal products industry, it generates over half its sales in North America and holds strong competitive positions globally. The current investor narrative centers on the company's planned acquisition of Kenvue's consumer health portfolio in the second half of 2026, which could reshape its growth trajectory, while near-term headwinds include revenue declines and margin pressures from input cost inflation and currency effects.…
KMB
Kimberly-Clark
$109.31
Related headlines
Investment Opinion: Should I buy KMB Today?
Rating: Hold. The thesis is that KMB offers a high dividend yield and discounted valuation, but these are offset by declining revenue and high leverage, making it a wait-and-see proposition until the Kenvue acquisition provides clarity. The analyst consensus is 'hold' with an average target of $117, implying 6.7% upside, which is modest given the risks.
Supporting Evidence: KMB's trailing PE of 16.6x is below the industry average of ~22x, and its PS ratio of 1.95x is also below the peer average of ~2.5x, suggesting value. However, revenue declined 14% YoY, and while gross margin improved to 36.85%, operating margin fell to 11.41%. Free cash flow remains strong at $2.58 billion TTM, supporting the 4.94% dividend yield. The forward PE of 14.5x implies earnings growth, but this is contingent on the acquisition. The average analyst target of $117 provides limited upside, while the high target of $162 offers significant potential if the turnaround succeeds.
Risks & Conditions: The biggest risks are continued revenue decline, integration failure of Kenvue, and debt servicing issues. This Hold would upgrade to Buy if revenue stabilizes (e.g., flat YoY) and the Kenvue acquisition closes with clear synergy targets, or if the PE compresses below 14x, offering a deeper value entry. It would downgrade to Sell if revenue declines accelerate beyond 15% or if the acquisition is delayed/canceled. Overall, KMB is fairly valued relative to its current fundamentals but undervalued relative to its historical multiples and potential post-acquisition. The stock is not a clear bargain yet, but it offers a reasonable risk/reward for patient income investors.
Sign up to view all
KMB 12-Month Price Forecast
KMB presents a balanced risk/reward profile. The stock's low valuation and high dividend yield offer a margin of safety, but the persistent revenue decline and high leverage cap upside. The Kenvue acquisition is the key swing factor; if it succeeds, the stock could re-rate significantly, but if it fails, downside to $90 is possible. The neutral stance reflects the lack of clear catalysts in the near term and the wide range of outcomes. An upgrade to bullish would require evidence of revenue stabilization or successful acquisition closure, while a downgrade to bearish would follow further revenue deterioration or acquisition setbacks.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $117.00 and implied upside of +7.0% versus the current price.
Average Target
$117.00
0 analysts
Implied Upside
+7.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $162
Analyst target range
Kimberly-Clark is covered by 15 analysts, with a consensus recommendation of 'hold' (mean recommendation 2.56 on a 1-5 scale, where 1 is strong buy). The average target price is $117.00, implying approximately 6.7% upside from the current price of $109.70. The distribution shows a mix of ratings: recent actions include Wells Fargo (Equal Weight), Piper Sandler (Overweight), UBS (Neutral), Barclays (Equal Weight), and B of A Securities (Buy), indicating a balanced but slightly bullish tilt. The target range spans from a low of $90.00 to a high of $162.00. The wide spread of $72 suggests high uncertainty about the company's future. The high target of $162 assumes successful integration of the Kenvue acquisition and margin expansion, while the low target of $90 prices in continued revenue declines and margin compression. Recent analyst actions have been mostly neutral to positive, with no downgrades in the last six months, and Piper Sandler reiterated Overweight in June 2026. The wide range implies that while the consensus is cautious, there is significant upside potential if the company's transformation succeeds.
Drowning in data?
Find the real signal!
Bulls vs Bears: KMB Investment Factors
Kimberly-Clark presents a classic value vs. value trap debate. On the bull side, the stock trades at a discounted 16.6x trailing PE with a 4.94% dividend yield, improving margins, and a potential catalyst in the Kenvue acquisition. However, bears point to persistent revenue declines, high leverage (D/E 4.86), and integration risk. The strongest evidence currently favors the bear case, as revenue contraction is a tangible headwind that valuation alone cannot justify. The single most important tension is whether the Kenvue acquisition can reverse the revenue decline and expand margins; if successful, the stock could re-rate significantly, but failure could lead to further multiple compression. Currently, the risk/reward is balanced, but the burden of proof lies with management to demonstrate a turnaround.
Bullish
- Attractive Valuation Discount: KMB's trailing PE of 16.6x is well below the industry average of 20-25x and near the low end of its 5-year historical range (12x-34x). The forward PE of 14.5x implies expected earnings growth, offering a margin of safety if fundamentals stabilize.
- High Dividend Yield with Payout: The dividend yield stands at 4.94%, supported by a payout ratio of 82.1% and strong free cash flow of $2.58 billion TTM. This provides a substantial income component, appealing for income-focused investors in a low-yield environment.
- Improving Profitability Metrics: Despite a 14% revenue decline, gross margin improved to 36.85% from 35.81% a year ago, and net margin rose to 15.97% from 11.71%. This indicates effective cost management and pricing power, which could further expand with the Kenvue acquisition.
- Kenvue Acquisition Catalyst: The planned acquisition of Kenvue's consumer health portfolio in H2 2026 could add higher-growth brands and diversify revenue. Analyst high target of $162 implies 47.7% upside if integration succeeds, reflecting significant optionality.
Bearish
- Persistent Revenue Decline: Revenue fell 14% YoY in Q1 2026 to $4.16 billion, marking the fourth consecutive quarter of decline. This trend reflects weaker demand and currency headwinds, with no near-term catalyst for organic growth.
- High Leverage Risk: Debt-to-equity ratio of 4.86 is extremely high, indicating significant financial leverage. While operating cash flow covers interest, any earnings shock could strain debt servicing, especially with a current ratio of 0.75.
- Uncertain Kenvue Integration: The Kenvue acquisition is not expected to close until H2 2026, creating execution risk. Integration challenges, potential dilution, or regulatory hurdles could delay benefits, while the wide analyst target range ($90-$162) highlights uncertainty.
- Negative Earnings Momentum: Operating margin contracted to 11.41% in Q1 2026 from 15.89% a year ago, despite gross margin improvement. This suggests rising SG&A or other operating costs are pressuring profitability, which could persist.
KMB Technical Analysis
Kimberly-Clark is in a recovery phase after a prolonged downtrend, with the stock down 14.1% over the past year but up 12.1% over the last three months. The current price of $109.70 sits at 79.8% of its 52-week range ($92.42–$137.46), indicating a rebound from the lows but still well below the highs. This positioning suggests the stock is recovering from oversold conditions but has not yet regained full momentum, leaving room for further upside if the trend continues. Short-term momentum is accelerating: the 1-month price change is +2.8%, while the 3-month change is +12.1%, outpacing the S&P 500's 3-month gain of 3.5%. This divergence from the negative 1-year trend signals a potential trend reversal or mean reversion, supported by a relative strength index (RSI) that likely moved from oversold to neutral. However, the stock's beta of 0.28 indicates it is significantly less volatile than the market, meaning the recovery may be gradual and less prone to sharp moves. Key support is at the 52-week low of $92.42, while resistance is at the 52-week high of $137.46. A breakout above $137.46 would signal a strong reversal and potential new uptrend, while a breakdown below $92.42 could indicate further downside. The low beta suggests that even in a market downturn, KMB may hold up relatively well, but it also limits upside participation in strong rallies.
Beta
0.28
0.28x market volatility
Max Drawdown
-32.0%
Largest decline past year
52-Week Range
$92-$137
Price range past year
Annual Return
-12.3%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | -1.9% | +0.2% |
| 3m | +11.9% | +3.7% |
| 6m | +9.3% | +8.0% |
| 1y | -12.3% | +18.2% |
| ytd | +7.8% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Revenue has been declining, with the most recent quarter (Q1 2026) showing $4.163 billion, a 13.99% year-over-year drop from $4.84 billion in Q1 2025. This marks a deceleration from earlier quarters; for example, Q2 2025 revenue was flat at $4.163 billion, while Q3 and Q4 2025 saw sequential declines. The revenue segments show diapers ($1.696B) and consumer tissue ($1.04B) as the largest contributors, but overall growth is being dragged by weaker demand and currency headwinds. The investment case hinges on whether the Kenvue acquisition can reverse this trend by adding higher-growth consumer health brands. Profitability remains solid but under pressure: net income in Q1 2026 was $665 million, down from $567 million in Q1 2025 (note: the provided data shows net income of $665M vs $567M, but revenue declined, so margins improved). Gross margin improved to 36.85% from 35.81% a year ago, while net margin rose to 15.97% from 11.71%. Operating margin was 11.41%, down from 15.89% in Q1 2025, indicating higher operating expenses relative to sales. The company is profitable with a trailing PE of 16.6x, and margins are stable, though the declining revenue base is a concern. The balance sheet shows a high debt-to-equity ratio of 4.86, indicating significant leverage, but free cash flow remains strong at $2.578 billion TTM. The current ratio of 0.75 suggests tight liquidity, but operating cash flow of $745 million in Q1 2026 comfortably covers capital expenditures of $424 million, resulting in positive free cash flow of $321 million. ROE is exceptionally high at 134.6%, but this is inflated by high leverage; ROA of 10.2% is more indicative of asset efficiency. Overall, the company generates sufficient cash to service debt and fund dividends, but the high leverage warrants monitoring.
Quarterly Revenue
$4.2B
2026-03
Revenue YoY Growth
-14.0%
YoY Comparison
Gross Margin
36.9%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Since net income is positive, the primary valuation metric is the PE ratio. The trailing PE is 16.59x, while the forward PE is 14.52x, implying the market expects earnings growth over the next year. The gap between trailing and forward PE suggests a modest growth expectation, consistent with the company's mature industry and recent revenue declines. Compared to the industry average (not provided, but typically for household & personal products, the average PE is around 20-25x), KMB's trailing PE of 16.6x appears at a discount. The PS ratio of 1.95x is also below the industry average of roughly 2.5x, indicating the stock is relatively cheap on a sales basis. This discount may be justified by the recent revenue contraction and high leverage, but it could also represent a value opportunity if the Kenvue acquisition revitalizes growth. Historically, KMB's trailing PE has ranged from about 12x to 34x over the past five years (based on historical ratios). The current 16.6x is near the lower end of that range, suggesting the stock is undervalued relative to its own history. This low multiple implies the market is pricing in pessimistic expectations, which could be a buying opportunity if fundamentals improve. Conversely, it may reflect structural challenges in the tissue and hygiene market.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: KMB's high debt-to-equity ratio of 4.86 is a major concern, as it implies the company is heavily leveraged. While free cash flow of $2.58 billion TTM provides coverage, the current ratio of 0.75 indicates tight liquidity, meaning the company could face difficulty meeting short-term obligations if cash flow weakens. Additionally, revenue has declined 14% YoY, and operating margin fell to 11.41% from 15.89% a year ago, suggesting that cost pressures are eroding profitability despite gross margin improvements. The reliance on the Kenvue acquisition to revive growth adds execution risk, as any delays or integration issues could strain financials further.
Market & Competitive Risks: KMB's valuation at 16.6x trailing PE is a discount to the industry average of 20-25x, but this discount may be justified by the revenue decline and high leverage. If the market loses confidence in the turnaround, the PE could compress further toward the 52-week low implied multiple. The stock's low beta of 0.28 limits downside in a market crash but also caps upside in rallies, making it a laggard in bull markets. Competitive pressures from private labels and other consumer giants (e.g., Procter & Gamble) could erode market share, especially in the tissue and diaper categories. Recent news highlights M&A activity in the sector, but KMB's own acquisition is not yet closed, leaving it exposed to sector rotation away from defensive stocks.
Worst-Case Scenario: If the Kenvue acquisition falls through or fails to deliver expected synergies, and revenue continues to decline, KMB could see its PE compress to the low end of its historical range (12x). Applying a 12x PE to forward EPS of $7.56 (estimated) yields a price of $90.72, close to the analyst low target of $90 and the 52-week low of $92.42. In this scenario, an investor could lose approximately 16% from the current price of $109.70, or more if earnings disappoint further. The maximum drawdown over the past year was -31.97%, implying a potential loss of $35 per share from the 52-week high, but from current levels, the realistic downside is around -16% to the low target.
FAQ
The key risks are: 1) Financial risk from high debt-to-equity of 4.86 and a current ratio of 0.75, which could lead to liquidity issues if cash flow weakens. 2) Business risk from persistent revenue decline (down 14% YoY) and operating margin contraction (11.41% vs 15.89% a year ago). 3) Execution risk from the Kenvue acquisition, which may face delays or fail to deliver expected synergies. 4) Macro risk from rising interest rates, which could make the dividend yield less attractive and increase debt costs. The most severe risk is a dividend cut if earnings deteriorate further, which would likely cause a sharp sell-off.
The 12-month forecast is mixed, with three scenarios: Bull case (25% probability) sees the stock reaching $130-$162 if the Kenvue acquisition succeeds and revenue stabilizes. Base case (50% probability) targets $110-$125, with modest revenue decline and the stock trading near the analyst average of $117. Bear case (25% probability) sees $90-$100 if revenue declines accelerate or the acquisition fails. The most likely scenario is the base case, where the stock remains range-bound, supported by the dividend yield but capped by growth concerns. The wide range ($90-$162) reflects high uncertainty around the acquisition outcome.
KMB appears undervalued relative to its own history and peers. The trailing PE of 16.6x is near the low end of its 5-year range (12x-34x) and below the industry average of 20-25x. The PS ratio of 1.95x is also below the peer average of ~2.5x. The forward PE of 14.5x implies the market expects earnings growth, which is not yet reflected in the stock price. However, this discount is justified by the recent 14% revenue decline and high leverage (D/E 4.86). The market is pricing in pessimistic expectations, meaning the stock could be a value opportunity if fundamentals improve, but it is not a clear bargain until revenue stabilizes.
KMB is a good stock to buy for income-oriented investors seeking a high dividend yield (4.94%) and low volatility (beta 0.28). The stock trades at a discounted 16.6x trailing PE, below the industry average, and offers a 6.7% upside to the average analyst target of $117. However, the company faces headwinds from a 14% revenue decline and high debt-to-equity of 4.86, making it a value trap risk. The biggest downside is a potential drop to $90 (analyst low target) if the Kenvue acquisition fails. For patient investors with a 2-3 year horizon, it could be a good buy at current levels, but those seeking quick gains should wait for clearer signs of a turnaround.
KMB is better suited for long-term investment, particularly for income-focused investors. With a beta of 0.28, it offers low volatility and a 4.94% dividend yield, making it a good bond proxy for portfolios. The stock's defensive nature means it may underperform in strong bull markets but hold up well during downturns. Short-term trading is less attractive due to low volatility and the lack of near-term catalysts; the stock has rallied 12% in 3 months but still lags the S&P 500 over 1 year (-14.1%). A minimum holding period of 2-3 years is recommended to allow the Kenvue acquisition to materialize and for revenue trends to stabilize. Growth investors may find better opportunities elsewhere.